Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia;Rosuvastatina y metformina reducen la inflamación y el estrés oxidativo en pacientes con hipertensión y dislipemia

Revista Espanola de Cardiologia

Volumn 60, Issue 12, 2007, Pages 1242-1249

  Gómez García, Anel ^a,c   Torres, Gloria Martínez ^a   Ortega Pierres, Luz E ^b   Rodríguez Ayala, Ernesto ^a   Álvarez Aguilar, Cleto ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD MICHOACANA DE SAN NICOLÁS DE HIDALGO   (Mexico)

^c NONE   (Mexico)

Author keywords

Cardiovascular risk; Drugs; Inflammation; Oxidative stress; Pleiotropic effects

Indexed keywords

CHOLESTEROL; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; ROSUVASTATIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MALE; OPEN STUDY; OXIDATIVE STRESS; RISK MANAGEMENT;

EID: 37349102447     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13113929     Document Type: Article

References (46)

1. Velázquez Monroy O, Rosas Peralta M, Lara Esqueda A, Pastellín Hernández G, Grupo ENSA 2000, Fause Attie, et al. Hipertensión arterial en México: Resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex. 2002;72:71-84.
2. Collins R, Peto R, Macmahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood Pressure, stroke and coronary artery disease. Part 2. Short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-38.
3. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol. 1999;19:2355-63.
4. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38:399-403.
5. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867-72.
6. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381-478.
7. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 1997;39:287-324.
8. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105:1656-62.
9. Treasure CB, Klein JL, Weintraub WS, Talley D, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-7.
10. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension. 1999;33:719-25.
11. Tello A, Marín F, Roldán V, García-Herola A, Lorenzo S, Climent VE, et al. Efecto de dosis máximas de atorvastatina en la inflamación, la trombogénesis y la función fibrinolítica en pacientes con cardiopatía isquémica de alto riesgo. Rev Esp Cardiol. 2005;58:934-40.
12. Pavlovic D, Kocic R, Kocic G, Tevtovic T, Radenkovic S, Mikic D, et al. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diab Obes Metab. 2000;2:251-6.
13. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-9.
14. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: Lipid reduction and beyond. J Clin Endocrinol Metab. 2002;87:1451-8.
15. Lucas AR, Korol R, Pepine CJ. Inflammation in atherosclerosis: some thoughts about acute coronary syndromes. Circulation. 2006;113:e728-32.
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
17. Jeyaseelan L, Rao PSS. Methods of determining sample sizes in clinical trials. Indian Pediatrics. 1989;26:115-21.
18. Dallondville J. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prev Rehabil. 2003;10:S2-78.
19. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-72.
20. Kim SH, Abbasi F, Reaven GM. Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care. 2004;27:1998-2002.
21. Vázquez LA, Pazos F, Berrazueta JR, Fernández-Escalante C, García-Unzueta MT, Freijanes J, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90:316-22.
22. Anurag P, Anuradha CV. Metformin improves lipid metabolism and attenuates lipid peroxidation in high fructose-fed rats. Diabetes Obes Metab. 2002;4:36-42.
23. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993;16:1387-90.
24. Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab. 2007;9:330-6.
25. Kiayias JA, Vlachou ED, Papadodima EL. Metformin and lipoprotein(a) levels. Diabetes Care. 1999;22:859.
26. Nagi DK, Mohamed AV, Yudkin JS. Effect of metformin on intact proinsulin and des 311, 32 proinsulin concentrations in subjects with non-insulin-dependent (Type 2) diabetes mellitus. Diabetic Med. 1996;13:753-7.
27. Goodarzi MO, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab. 2005;7:654-65.
28. Rodríguez-Moctezuma JR, Robles-López G, López-Carmona JM, Gutiérrez-Rosas MJ. Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes Obes Metab. 2005;7:189-92.
29. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:e55.
30. Duarte Pedraza L, Castillo Pineda JC, Ramírez Enríquez J, Ibarra Ramírez F, Gómez García A, Álvarez Aguilar C. Efecto de la metformina en el peso corporal y perfil metabólico en mujeres con obesidad. Nutrición Clínica. 2006;7:36-42.
31. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformina on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
32. Dandona P, Aljada A, Chaudhuri A, Bandyopadhyay A. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab. 2003;88:2422-9.
33. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002;252:283-94.
34. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-26.
35. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of IL6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-72.
36. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002;86:5-18.
37. Liao JK. Role of statin pleiotropism in acute coronary syndromes and stroke. Int J Clin Pract Suppl. 2003;134:51-7.
38. Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis. 2003;14:329-34.
39. Caballero AE, Delgado A, Aguilar-Salinas CA, Naranjo Herrera A, Castillo JL, Cabrera T, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled randomized clinical trial. J Clin Endocrinol Metab. 2004;89:3943-8.
40. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001;77:247-53.
41. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-50.
42. Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab. 2006;91:4489-96.
43. Chen LF, Greene WC. Shaping the nuclear action of NF-kB. Molecular Cell Biology. 2004;5:392-401.
44. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, et al. Insulin inhibits intranuclear factor kB and stimulates IkB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001;86: 3257-62.
45. Hilgendorff A, Muth H, Parviz B, Staubitz A, Haberbosh W, Tillmanns H, et al. Statins differ in their ability to block NF-kB activation in human blood monocytes. Int J Clin Pharmacol Ther. 2005;41:397-401.
46. Gongora MC, Qin Z, Laude K, Kim HW, McCann L, Folz JR, et al. Role of extracellular superoxide dismutase in hypertension. Hypertension. 2006;48:473-81.